


DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)



<u>Dosing</u> Biologic		Radiographic ankylosing spondylitis (AS)			Non radiographic axial spondyloarthritis (nrAS)			Deenence
		NICE TA	Loading dose	Maintenance dose	NICE TA	Loading dose	Maintenance dose	Response measured
Subcutaneous	preparations	Ţ						
Adalimumab (SC)	Monoclonal antibodies	TA383	40mg every 2 weeks	NA	TA383	40mg every 2 weeks	NA	12 Weeks
Bimekizumab (SC)	Human monoclonal antibody selective for IL-17F and IL17A, 17AF	TA918	160mg every 4 weeks	NA	TA918	160mg every 4 weeks	NA	16 weeks
Certolizumab (SC)	Monoclonal antibody	TA383	400mg (2x 200mg) given at Week 0, 2 & 4	200mg every 2 weeks or 400mg every 4 weeks	TA383	400mg (2x 200mg) given at Week 0, 2 & 4	200mg every 2 weeks or 400mg every 4 weeks	12 weeks
Etanercept (SC)	Recombinant human TNF receptor fusion protein	TA383	50mg once weekly Or 25mg twice weekly	NA	TA383	50mg once weekly	NA	12 weeks
Golimumab (SC)	Monoclonal antibody	TA475	50mg every month >100kg in body weight, (& disease does not respond after 4x50mg doses), increase dose to 100mg every month	NA	TA497	50mg every month >100kg in body weight, (& disease does not respond after 4x50mg doses), increase dose to 100mg every month	NA	12-14 weeks
lxekizumab (SC)	Human monoclonal antibody selective for IL-17A	TA718	160mg (2x 80mg) given at Week 0	80mg every 4 weeks	TA718	160mg (2x 80mg) given at Week 0	80mg every 4 weeks	16-20 weeks
Secukinumab (SC)	Human monoclonal antibody selective for IL-17A	TA407	Week 0,1,2 & 3 – 150mg	Week 4 – 150mg & then continue every month	TA719	Week 0,1,2 & 3 – 150mg	Week 4 – 150mg & then continue every month	16 weeks

Intravenous infusion										
Infliximab (IV)	Monoclonal antibodies	TA383	5mg/kg IV at week 0, 2 & 6	5mg/kg IV every 6-8 weeks thereafter				6 weeks		
Oral therapies Tofacitinib (PO)	Inhibitor of JAK1 and	TA920	5mg taken twice daily	NA	NA	NA	NA	16 weeks		
(FO)	JAK3									
Upadacitnib (PO)	Selective and reversible inhibitor of the Janus- associated tyrosine kinase JAK1	TA829	15mg taken once daily	NA	TA861	15mg taken once daily	NA	16 weeks Some patients with initial partial response may subsequently improve with continued treatment beyond 16 weeks.		